Biogen Inc   (BIIB)
Other Ticker:  
Price: $199.6500 $6.56 3.397%
Day's High: $199.78 Week Perf: 0.64 %
Day's Low: $ 194.50 30 Day Perf: -8.59 %
Volume (M): 973 52 Wk High: $ 468.55
Volume (M$): $ 194,160 52 Wk Avg: $267.51
Open: $195.33 52 Wk Low: $187.16

 Market Capitalization (Millions $) 29,468
 Shares Outstanding (Millions) 148
 Employees 9,100
 Revenues (TTM) (Millions $) 10,820
 Net Income (TTM) (Millions $) 1,542
 Cash Flow (TTM) (Millions $) 568
 Capital Exp. (TTM) (Millions $) 242

Biogen Inc
Biogen Idec creates new standards of care in oncology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, we transform scientific discoveries into advances in human healthcare. We currently have four commercial products: AVONEX® (Interferon beta-1a) for the treatment of relapsing multiple sclerosis, also known as MS, RITUXAN® (rituximab) and ZEVALIN® (ibritumomab tiuxetan), both of which treat certain B-cell non-Hodgkin’s lymphomas, also referred to as B-cell NHLs, and AMEVIVE® (alefacept) for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Our sales and marketing efforts are generally focused on specialist physicians in private practice or at major medical centers. We utilize common pharmaceutical company practices to market our products and to educate physicians, including sales representatives calling on individual physicians and distributors, advertisements, professional symposia, direct mail, selling initiatives, public relations and other methods. We have also established uninsured patient programs in the U.S.  for our marketed products which provide qualified patients with products at no charge. We also provide certain customer service and other related programs for our products, such as disease and product-specific websites, insurance verification services and order, delivery and fulfillment services.

Competition in the biotechnology and pharmaceutical industries is intense and comes from many and varied sources. We do not believe that any of the industry leaders can be considered dominant in view of the rapid technological change in the industry. We experience significant competition from specialized biotechnology firms in the U.S., the EU and elsewhere and from many large pharmaceutical, chemical and other companies.


AVONEX competed in the U.S. and EU markets primarily with three products:

• BETASERON®, sold by Berlex in the U.S. and sold under the name BETAFERON® by Schering A.G.

• REBIF®, which is co-promoted by Serono, Inc. and Pfizer in the U.S. and sold by Serono AG in the EU.

• COPAXONE® glatiramer acetate, sold by Teva Neuroscience, Inc. in the U.S. and co-promoted by Teva and Aventis Pharma in the EU.

RITUXAN is typically used after patients fail to respond or relapse after treatment with traditional radiation therapy or standard chemotherapy regimes, such as CVP and CHOP. ZEVALIN is typically used after patients fail to respond or relapse following treatment with RITUXAN. ZEVALIN competes with BEXXAR® (tositumomab, iodine I-131 tositumomab), a radiolabeled molecule developed by Corixa Corporation and GlaxoSmithKline. BEXXAR received FDA approval in June 2003 to treat patients with CD20+, follicular, NHL, with and without transformation, whose disease is refractory to RITUXAN and has relapsed following chemotherapy.


AMEVIVE competes with several different types of therapies including:

• traditional therapies for moderate-to-severe chronic plaque psoriasis, such as oral retinoids, steroids, methotrexate, cyclosporin, PUVA and UVB radiation.

• RAPTIVA® (efalizumab), a drug co-developed by Genentech and Xoma Corporation that was approved by the FDA in November 2003 to treat moderate-to-severe psoriasis. Serono has an exclusive license to RAPTIVA in the EU and other countries and has filed for regulatory approval of the drug in the EU. Drugs approved for other indications that are used to treat psoriasis. Among these drugs are ENBREL® (etanercept), REMICADE® (infliximab) and HUMIRA®(adalimumab). ENBREL is sold by Amgen, Inc. and Wyeth Pharmaceuticals, Inc. and is approved to treat psoriatic arthritis. In January 2003, Amgen announced positive results from a Phase 3 clinical study of ENBREL in the treatment of moderate-to-severe plaque psoriasis and is conducting a second Phase 3 clinical study in psoriasis. REMICADE is sold worldwide by Centocor, Inc., a subsidiary of Johnson & Johnson, as a treatment for other indications, including rheumatoid arthritis, and is currently in a Phase 2 proof of concept study as a potential treatment for psoriasis. HUMIRA is sold by Abbott Laboratories and is approved to treat rheumatoid arthritis. Abbott is undertaking clinical trials in psoriasis and psoriatic arthritis.

   Company Address: 225 Binney Street Cambridge 2142 MA
   Company Phone Number: 679-2000   Stock Exchange / Ticker: NASDAQ BIIB
   BIIB is expected to report next financial results on July 21, 2022.

Customers Net Income grew by BIIB's Customers Net Profit Margin fell to

2.52 %

4.49 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

Year to Date Decrease / Increase
ABBV        11.51% 
AMGN        9.18% 
ABT   -18.56%    
BMY        23.13% 
JNJ        3.17% 
MRK        21.7% 
PFE   -7.38%    
• View Complete Report

Arboretum Silverleaf Income Fund L.p.

disclosed financial first quarter of 2022 operating profit of $0.129046 millions

In the financial first quarter of 2022 loss increased of $-0.01 per share compared to $0.03 a year ago and from $-0.01 per share from the previous quarter.

Sun Pacific Holding Corp

Break-even by Sun Pacific Holding Corp in the fiscal period ending Mar 31 2022 report

In the fiscal period ending Mar 31 2022 Sun Pacific Holding Corp reached break-even of $0.00 per share compared to $-0.00 a year ago and from $0.00 per share from the previous quarter.

Stemtech Corporation

Deficit Bigger Than a Year Ago but Revenues Unchanged at Stemtech Corporation in the fiscal first quarter of 2022

In the fiscal first quarter of 2022 Stemtech Corporation loss increased of $-0.01 per share compared to $-0.00 a year ago and improved from $-0.02 per share from the previous quarter.

Vivos Therapeutics Inc.

Vivos Therapeutics Inc reported that Sales has tumbled in the most recent fiscal period

In the most recent fiscal period Vivos Therapeutics Inc lost money of $-0.26 per share compared to $-0.96 a year ago and eps fell from $0.43 per share from the previous quarter.

Ezagoo Limited

Ezagoo Limited declared that Sales has tumbled in the financial span ending Mar 31 2022

Ezagoo Limited recorded operating loss of $-0.180595 millions, in the financial span ending Mar 31 2022, a degradation from the operating profit of $0.298338 millions, reported in first quarter of 2021


Biogen Inc 's Segments
 Segment    29.25 % of total Revenue
 Segment    22.02 % of total Revenue
 Segment    3.54 % of total Revenue
 Segment    -3.94 % of total Revenue
 Segment    1 % of total Revenue
 Segment    42 % of total Revenue
 Segment    2.59 % of total Revenue
 Segment    3.53 % of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Biogen Inc does not provide revenue guidance.

Earnings Outlook
Ezagoo Limited does not provide earnings estimates.

Geographic Revenue Dispersion
United States 74.12 %
Europe 15.3 %
Asia 8.74 %
Other 1.84 %


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

JHX's Profile

Stock Price

JHX's Financials

Business Description


Charts & Quotes

JHX's News


JHX's Competitors

Customers & Markets

Economic Indicators

JHX's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries






About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071